« Return to News | CROs/Service Providers

inVentiv Health completes i3 acquisition

Monday, June 13, 2011 09:56 AM

inVentiv Health has completed the acquisition of CRO i3. i3, previously owned by Ingenix, a UnitedHealth Group company.

inVentiv's clinical segment will be comprised of i3, along with inVentiv's existing clinical businesses and PharmaNet Development Group, which inVentiv announced it would acquire in May. As a combined entity, inVentiv's clinical segment will have more than 6,000 employees dedicated to clinical research in nearly 40 countries, including emerging markets in Asia, Latin America and Central/Eastern Europe.

Paul Meister, CEO of inVentiv Health, said, "As pharmaceutical companies continue to seek enhanced flexibility and lower fixed costs, demand for best-in-class clinical outsourcing services has never been greater. inVentiv is moving quickly to seize this opportunity by establishing itself as a leading global provider of CRO services. The acquisition of i3 is a critical step toward this goal.”

"In an industry that is both dynamic and volatile, having a strategic vision for growth is essential," said Glenn Bilawsky, CEO of i3.  "inVentiv is an ideal partner for us because they not only see the potential opportunity for i3, they bring the foresight, passion and resources to take us there.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.